| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |






From the Department of Cell and Molecular
Biology,*
Imgenex Corporation, San Diego, California; the
Departments of Pathology and Laboratory Medicine and
Pathology,
University of Arkansas for Medical
Sciences, Little Rock, Arkansas; the Department of
Pediatrics,
Kyoto Prefectural University of
Medicine, Kyoto, Japan; the Department of
Molecular Pharmacology,§
St. Jude Childrens
Research Hospital, Memphis, Tennessee; and the
Pediatric Division,¶
Cooperative Human Tissue
Network, Childrens Hospital, Columbus, Ohio
Rhabdomyosarcomas are a heterogeneous group of tumors with respect to their molecular basis, degree of differentiation, histology, and clinical behavior. Because of the wide variation of tumor morphology, it is often difficult to distinguish between the distinct subtypes of rhabdomyosarcomas. By using cryosections of tumor specimens and immunohistochemistry, in the present study we show that strong expression of myogenin in rhabdomyosarcoma is associated with alveolar histology (P = <0.0001, Fishers exact test). Although staining for myogenin was observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high levels of staining for myogenin, as defined by the frequency and intensity of staining of the tumor cells. The staining pattern suggests that the tumor cells are clonally derived from myogenin-positive progenitor cells. In contrast, most embryonal rhabdomyosarcomas (13 of 15) were either negative or showed a low level of staining for myogenin. In these tumors a larger proportion of tumor cells were distinctly negative for myogenin. Six of seven alveolar rhabdomyosarcomas that strongly stained for myogenin were also positive for Pax37/Forkhead (FKHR) by polymerase chain reaction/reverse transcriptase-polymerase chain reaction. One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts. Quantitative analysis for myogenin by Western blotting using a smaller subset of rhabdomyosarcomas revealed that in general there was a good correlation between immunohistochemical staining and Western blotting (P = 0.01, Pearson Correlation), although the former technique was more sensitive for detecting tumors with low levels of the protein. On average, alveolar rhabdomyosarcomas expressed at least threefold more myogenin than embryonal rhabdomyosarcomas. Our data show that staining for myogenin will be a simple, rapid, and accurate adjunct for distinguishing between alveolar and embryonal rhabdomyosarcomas. We propose that embryonal rhabdomyosarcomas result from an early block in myogenesis, before the expression of myogenin. In contrast, we propose that alveolar rhabdomyosarcomas either originate from a late block in myogenesis (after expression of myogenin) or that the pathological mechanisms involved in these neoplasms also induce strong expression of this protein.
This article has been cited by other articles:
![]() |
J.-J. Hu, A. Ambrus, T. W. Fossum, M. W. Miller, J. D. Humphrey, and E. Wilson Time Courses of Growth and Remodeling of Porcine Aortic Media During Hypertension: A Quantitative Immunohistochemical Examination J. Histochem. Cytochem., April 1, 2008; 56(4): 359 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Chamberlain, J. Metzger, M. Reyes, D. Townsend, and J. A. Faulkner Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma FASEB J, July 1, 2007; 21(9): 2195 - 2204. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wachtel, T. Runge, I. Leuschner, S. Stegmaier, E. Koscielniak, J. Treuner, B. Odermatt, S. Behnke, F. K. Niggli, and B. W. Schafer Subtype and Prognostic Classification of Rhabdomyosarcoma by Immunohistochemistry J. Clin. Oncol., February 10, 2006; 24(5): 816 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R.J. Bois, K. Izeradjene, P. J. Houghton, J. L. Cleveland, J. A. Houghton, and G. C. Grosveld FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma J. Cell Biol., September 12, 2005; 170(6): 903 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
N J Sebire and M Malone Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas J. Clin. Pathol., June 1, 2003; 56(6): 412 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Brey, Z. Lalani, C. Johnston, M. Wong, L. V. McIntire, P. J. Duke, and C. W. Patrick Jr. Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification J. Histochem. Cytochem., May 1, 2003; 51(5): 575 - 584. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |